3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
8
Recruiting
5
Terminated
2
Enrolling by invitation
1
Sponsor Class
OTHER
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
473
Carcinoma, Non-Small-Cell Lung
447
Breast Neoplasms
331
Neoplasm Metastasis
242
Colorectal Neoplasms
214
Melanoma
213
Leukemia, Myeloid, Acute
191
Multiple Myeloma
180
Recurrence
169
Ovarian Neoplasms
169
Prostatic Neoplasms
163
Lymphoma, Non-Hodgkin
148
Lung Neoplasms
134
Pancreatic Neoplasms
125
Lymphoma
123
Carcinoma, Renal Cell
112
Squamous Cell Carcinoma of Head and Neck
110
Leukemia, Lymphocytic, Chronic, B-Cell
110
Stomach Neoplasms
92
Carcinoma, Hepatocellular
89
Lymphoma, Large B-Cell, Diffuse
88
Leukemia
87
Triple Negative Breast Neoplasms
86
Lymphoma, Follicular
82
Head and Neck Neoplasms
79
Glioblastoma
74
Myelodysplastic Syndromes
70
Urinary Bladder Neoplasms
68
Small Cell Lung Carcinoma
64
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Interventions
Natalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
INDUSTRY
×
Multiple Sclerosis
×
Clear all
NCT03283826
2024-02-23
EMBOLD
Atara Biotherapeutics
Phase 1/2
Terminated
134 enrolled
NCT01416181
2017-09-11
ASCEND in SPMS
Biogen
Phase 3
Terminated
889 enrolled
31 charts